Active immunisation of mice with GnRH lipopeptide vaccine candidates: importance of T helper or multi-dimer GnRH epitope
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Introduction
Our understanding and approaches to block or limit the release of reproductive hormones in an attempt to limit their influence on cancers has progressed to the development of immunotherapies. In spite of low immunogenicity, active immunisation against gonadotropin releasing hormone (GnRH) has received considerable attention because of potential applications in immunocontraception. An active area of research is the development of synthetic GnRH-based vaccines against reproductive hormone-dependent male and female cancers. 1 Studies have shown that immunisation against GnRH can reduce prostate levels of testosterone similar to surgical castration in numerous mammalian models, including mice and humans. 2, 3 Immunisation of both males and females against GnRH can have a profound effect on fertility through the reduction in sex steroids and cessation of gametogenesis.
Hence, there is a potential for GnRH therapeutics to be used either as a semi-permanent contraceptive or to extend the postnatal anovulatory period. 4, 5 In the 1970s a number of groups attempted to produce antibodies against GnRH by coadministration with Complete Freund's Adjuvant (CFA). However, these attempts were unsuccessful in producing high anti-GnRH antibody titers. 6 Many small molecules like peptides (haptens) are successful immunogens only if they are attached to macromolecules (carriers). It is often necessary to modify these haptens for coupling with carriers to make a stable carrier-hapten complex. 7 Selection of a suitable carrier system, hapten density (hapten:carrier molar ratio), and conjugation methods are critical for developing an optimal vaccine against haptens. 8, 9 The first alum-adjuvanted vaccine which was successful in producing antibodies against GnRH was conjugated to a tetanus toxoid carrier. 10 A number of other fusion proteins have been prepared for the production of anti-GnRH antibodies that employ conjugation to diphtheria toxoid (e.g. Improvac®), keyhole limpet hemocyanin (e.g. GonaCon™) or ovalbumin, with many of them available commercially for veterinary use. [11] [12] [13] [14] [15] Another recombinant fusion protein consisting of GnRH and diphtheria toxoid was successful in phase I/II clinical trials. 16 Synthetic subunit vaccine systems eliminate the need for large carrier proteins, which are often associated with adverse effects in the host. 17 Since subunit vaccines are composed of different individual components (i.e. epitopes, carriers, adjuvants), they are highly customisable. This makes them valuable tools for developing vaccines against weak immunogens, such as GnRH. 18 Lipopeptides can form a synthetic subunit vaccine as one entity that includes all components (adjuvant, carrier and antigen) required by a successful vaccine, eliminating the need for co-administration with an adjuvant. 19, 20 High antibody titers were generated when multiple copies of a peptide were incorporated into a multiple antigenic peptide system with a branched polylysine core. 20 Immunogenicity was further enhanced by the incorporation of lipoamino acid (LAA) residues with this polylysine system, which led to the development of novel candidates for vaccines against a variety of disease states, including cancer. The lipid moieties in the lipopeptide system serve to mimic the action of bacterial adjuvants such as Pam 3 Cys and Pam 2 Cys. 21 Lipopeptide constructs have been found to mediate significant immunogenic effects without additional adjuvants. 22, 23 The development of a GnRH-based subunit lipopeptide vaccine for use as an immunocontraceptive therapy has previously received attention.
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In this study, we aimed to define the minimal components necessary for the induction of a systemic immune response against GnRH. The immunogenicity of the GnRH decapeptide (EHWSYGLRPG) was enhanced by incorporating it into the lipopeptide systems.
Results and Discussion

Peptide synthesis
Lipopeptides 1-5 ( Figure 1 ) were synthesised by manual and microwave-assisted solid-phase protocols with Boc chemistry. 25 Lipidic moieties were prepared from their 1-bromoalkanes using the method of Gibbons et al. and were used as a mixture of enantiomers in subsequent synthesis. 26 Amino acid couplings involved an activation of residues with DIPEA in DMF, followed by in situ neutralization in the presence of HATU or HBTU. The carbohydrate core for vaccine construct 2 was synthesised from a D-glucose derivative that bore an adipate linker and four tert-butoxycarbonyl protected aminopropyl groups as attachment points for GnRH peptide epitopes. 27 
1:
( A similar construct (4) consisting of two C16 lipid moieties was therefore used in this study. To investigate the immunogenic potential of the GnRH epitope, four copies of a tandem GnRH dimer were synthesised on a poly-lysine lipopeptide to yield 8 copies of the epitope in total (5). The presentation of GnRH was enhanced by replacing the Gly residue at position 6 in the parent peptide sequence with a D-Cys (pEHWSYcLRPG 30 and conjugated to a linear T helper lipopeptide (6') using Michael addition ( Figure 2 ).
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The site-specific conjugation allowed for both terminal regions of GnRH to display the free amino groups important for immune system recognition (6). The lipopeptide was designed to have only two 16-carbon LAAs at the N-terminus, with an additional Ser spacer for improved solubility. These modifications led to improved yields (70%) compared to the original design that incorporated a lipidic tail similar to 3 (4%). In compounds 4 -6, serine residues were used as spacers between the lipid moiety and epitopes, a modification that was previously reported to enhance the immune response of lipopeptides. ]GnRH* to maleimide conjugated adjuvant (6'), to form 6.
In vitro peripheral blood mononuclear cell (PBMC) toxicity assay
Numerous methods exist to evaluate cellular toxicity; most of them use cell cultures to screen for toxicity by either observing changes in normal cell function or detecting dead cells with stain-based assays. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) bromide assay has been widely used for determining the cytotoxicity of compounds. represented as mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by the Dunnett's post hoc test and compared to the PBS group.
Murine immunogenicity of synthetic GnRH vaccine candidates
The first study was performed to determine the ability of the GnRH lipopeptides to induce an immune response when four copies of GnRH were incorporated into polylysine or carbohydrate scaffolds (1-3). Compounds 1-3 without T helper epitope were compared to compound 4, which consisted of one copy of GnRH along with a T helper epitope. All lipopeptide vaccine candidates were dissolved in PBS at a concentration of 1 µg.µL -1 and administered with CFA to adjuvant a significant response to each construct. It was proposed that the immunogenicity of the GnRH hapten would benefit from increased molecular weight, increased copy number (possible B-cell receptor clustering), and the incorporation of a lipid adjuvant. It was anticipated that GnRH linked by the lysine residues of the polylysine core (1 and 3) would produce a structure that was large enough to be recognised and processed by the immune system. Since the spatial arrangement may play a part in the immunogenicity of synthetic subunit vaccines, a carbohydrate scaffold was used as a peptide antigen carrier to assemble 2. However, the first study using compounds 1-4 showed that compound 4 administered with CFA was the only compound to produce significant GnRH-specific IgG antibody titers (Figure 4 ). This demonstrated that the lipopeptide system alone was insufficient to adjuvant GnRH and required the incorporation of the T helper epitope or another strategy to stimulate a significant immune response in this model. To this end we designed two additional compounds to improve the immunogenicity of the anti-GnRH vaccine construct. In a previous study multiple copies of GnRH was added to a fragment of human IgG and T helper epitope derived from measles virus. It was shown that a significantly greater antibody response was elicited compared to that with same sequence but only a single copy of GnRH epitope. 35 Interestingly, the vaccine candidate 6 in PBS induced slightly higher GnRH-specific IgG titers in mice than 4 with CFA ( Figure 5 ). Both constructs consisted of identical principal components (GnRH, T helper epitope and lipid adjuvant), yet arranged in different configurations and conjugated through alternate bonds and positions. Our findings are consistent with a previous study where thioester linkages elicited higher antibody titers when compared to a library of alternative bonds. 36 It was suggested that different spatial arrangements of antigen, carrier, and adjuvant, and the presence of different bonds were responsible for variation in antibody titers. 
Conclusion
This study outlines the synthesis, cytotoxicity and immunogenicity of a library of novel lipopeptide subunit vaccines for GnRH. Self-adjuvanting lipopeptide GnRH vaccine candidates that contained multiple GnRH monomer/dimer epitopes or a thioester-linked GnRH helper epitope system were identified and developed. The investigation of the structure-activity relationship and optimal epitope configuration reinforced that the inclusion of both B and T helper epitopes has a significant effect on systemic anti-GnRH IgG titers. It 42 2-Aminododecanoic acid was synthesised as described in the literature with 1-bromodecane and diethyl acetoamidomalonate. 26 The free amine of 2-aminohexadecanoic acid was then Boc-protected by reaction with di-tert-butyl dicarbonate in a basic environment as previously reported. 26, 43 C12 was prepared to afford the pure product in 54.0% yield ( 44 2-Aminohexadecanoic acid was synthesised as described in the literature with 1-bromotetradecane and diethyl acetoamidomalonate. The free amine of 2-aminohexadecanoic acid was then Boc-protected by reaction with di-tert-butyl dicarbonate in a basic environment as previously reported. 26 The C16 product was prepared to yield (78%) the pure product ( 
Experimental Section
Materials and methods
Unless
2-tert-Butoxycarbonylaminododecanoic acid lipoamino acid (Boc-C12-OH)
2-tert-Butoxycarbonylaminohexadecanoic acid lipoamino acid (Boc-C16-OH)
2-((1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)ethyl)amino)hexadecanoic acid
(Dde-C16-OH) 45 5,5-Dimethyl-1,3-cyclohexanedione (2.5 g, 17.8 mmol) was dissolved in DCM (15 mL). 4-Dimethylaminopyridine (435 mg) and TEA (5 mL) were then added and the mixture was stirred for 10min. Ac 2 O (2.2 mL) was added and the mixture was stirred under Ar for 2 days.
The solvent was removed in vacuo by co-evaporation of the crude product in ethyl acetate (EtOAc) (50 mL) with toluene and then washed with 5% HCl (3 x 50 mL) and dried with 
Synthesis of lipopeptides
All peptides were synthesised using standard manual solid phase peptide synthetic protocols and then purified by RP-HPLC. Lipopeptides 1-5 were synthesised using p-4-methyl benzhydryl amine (p-MBHA; substitution 0.45 mmol.g 
Thioester conjugation of [D-Cys 6 ]GnRH to maleimide adjuvant (6)
The maleimide-T helper peptide adjuvant system, 6' (2.0 mg), was dissolved in DMF (2 mL). in PBS (18 mL) was then added, the reaction degassed, and left to stir at r.t. under N 2 for 5 h.
The product (6) was then purified using RP-HPLC and characterised with ESI-MS. (calcd.
1895.1).
PBMC isolation and In vitro cell toxicity assay
Assay was undertaken with the approval from the University of Queensland Ethics 
Statistics
Statistical analysis was performed using a one-way ANOVA followed by the Tukey post hoc test. GraphPad Prism 5 software was used for statistical analysis, with p < 0.05 taken as statistically significant.
